CD4 and metastatic melanoma: This transgenic mouse was recently developed in our laboratory [18] using the HLA-A2 restricted high-affinity TCR reactive to human tyrosinase-derived peptide, YMDGTMSQV, isolated from class I-restricted CD4+ T cells from tumor infiltrating lymphocytes of a patient with metastatic melanoma [17].